Literature DB >> 31937928

Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients.

Kathryn T Maples1, Molly Maloy2, Sean Devlin3, Andrew Lin4, Lauren DeRespiris4, Meagan Griffin4, Carmen Lau4, Anthony J Proli4, Genovefa A Papanicolaou2,5, Susan K Seo2,5, Juliet N Barker2,5, Miguel-Angel Perales2,5, Sergio A Giralt2,5, Valkal Bhatt4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31937928     DOI： 10.1038/s41409-020-0785-9

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

Review 1.  How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh; Per Ljungman
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

2.  Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.

Authors:  Alex Ganetsky; Todd A Miano; Mitchell E Hughes; Robert H Vonderheide; David L Porter; Ran Reshef
Journal:  J Antimicrob Chemother       Date:  2015-04-16       Impact factor: 5.790

3.  Low mean post-transplantation tacrolimus levels in weeks 2-3 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors.

Authors:  Patrick A Hagen; William Adams; Scott Smith; Stephanie Tsai; Patrick Stiff
Journal:  Bone Marrow Transplant       Date:  2018-07-23       Impact factor: 5.483

4.  Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake.

Authors:  Yoshihisa Shitara; Kumiko Takeuchi; Yoshiko Nagamatsu; Satomi Wada; Yuichi Sugiyama; Toshiharu Horie
Journal:  Drug Metab Pharmacokinet       Date:  2012-01-13       Impact factor: 3.614

5.  Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation.

Authors:  A Ganetsky; A Shah; T A Miano; W-T Hwang; J He; A W Loren; E O Hexner; N V Frey; D L Porter; R Reshef
Journal:  Bone Marrow Transplant       Date:  2015-12-21       Impact factor: 5.483

6.  Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin.

Authors:  Rune Amundsen; Hege Christensen; Behnaz Zabihyan; Anders Asberg
Journal:  Drug Metab Dispos       Date:  2010-06-02       Impact factor: 3.922

Review 7.  Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.

Authors:  Mikko Niemi; Marja K Pasanen; Pertti J Neuvonen
Journal:  Pharmacol Rev       Date:  2011-01-18       Impact factor: 25.468

8.  Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation.

Authors:  Gary D Peksa; Kathryn Schultz; Henry C Fung
Journal:  J Oncol Pharm Pract       Date:  2014-06-17       Impact factor: 1.809

9.  Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.

Authors:  Andrew Lin; Molly Maloy; Yiqi Su; Valkal Bhatt; Lauren DeRespiris; Meagan Griffin; Carmen Lau; Anthony Proli; Juliet Barker; Brian Shaffer; Sergio A Giralt; Ann A Jakubowski; Esperanza B Papadopoulos; Genovefa A Papanicolaou; Susan K Seo; Miguel-Angel Perales
Journal:  Transpl Infect Dis       Date:  2019-10-21       Impact factor: 2.228

10.  Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.

Authors:  Dirk Kropeit; Oliver von Richter; Hans-Peter Stobernack; Helga Rübsamen-Schaeff; Holger Zimmermann
Journal:  Clin Pharmacol Drug Dev       Date:  2017-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.